REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

WHO does not expect mass Covid-19 vaccinations before mid-2021

Fri, 04th Sep 2020 12:28

(Sharecast News) - The World Health Organization said on Friday it does not expect widespread vaccinations for Covid-19 until at least mid-2021.

A spokeswoman for the organization, Margaret Harris, said that it was of utmost importance to carry out enough safety and effectivity checks on the treatments before distributing them in mass.

She added that none of the vaccines currently in development had demonstrated a "clear signal" of efficacy at the level of at least 50%.

"We are really not expecting to see widespread vaccination until the middle of next year", Harris told a UN briefing in Geneva.

"This phase 3 must take longer because we need to see how truly protective the vaccine is and we also need to see how safe it is", she added. Phase 3 is a stage of clinical trials where the potential vaccine is tested on people.

The WHO is currently leading a global plan called COVAX in which over 150 countries have allied to work together to find an effective way to combat the virus that has halted the world.

Harris added that the aim of COVAX is for everyone in need of the vaccine to have access to it once it has been approved and is ready for distribution.

Also on Friday, according to a peer-reviewed study published in The Lancet, Russia's "Sputnik-V" vaccine had succeeded in producing an antibody and T-cell response in all the participants in phase 1 and 2 clinical trials.

All 76 patients responded positively to the treatment and no dangerous side-effects were registered.

Recruitment of 40,000 volunteers for a phase three clinical trial to assess efficacy was already under way.

Related Shares

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...

8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4% *

8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...

8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemi...

8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.